CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Reports

We found 77 result(s)

vortioxetine hydrobromide (Trintellix )

Last Updated: April 8, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: vortioxetine hydrobromide
Indications: Major depressive disorder (MDD), adults.

  • Brand Name: Trintellix
  • Manufacturer: Lundbeck Canada Inc.
  • Project Number: SR0611-000
  • Project Status: Complete
  • Submission Type: Initial

Major Depressive Disorder – Focused Critical Appraisal of a Network Meta-Analysis

Last Updated: February 18, 2020
Result type: Reports
Product Line: Technology Review
Research Type: Drug

Major depressive disorder (MDD) is a common, debilitating, and recurrent mental health disorder. Over the past decades, multiple classes of antidepressant drugs have been developed to treat this condition. The relative effectiveness and safety of antidepressants are uncertain. This project will review a recently published network meta-analysis f...

  • Project Number: HE0022-000

Internet-Delivered Cognitive Behavioural Therapy for Major Depressive Disorder and Anxiety Disorders: A Health Technology Assessment

Last Updated: July 22, 2019
Result type: Reports
Product Line: Optimal Use
Research Type: Device

Major depressive disorder (MDD) is the occurrence of one or more major depressive episodes that last at least two weeks. Anxiety disorders include a range of conditions, including generalized anxiety disorder, panic disorder, and social anxiety disorder. MDD and anxiety disorders may be treated with pharmacological and/or psychological intervent...

  • Project Number: OP0534-000

Esketamine for Treatment-Resistant Depression

Last Updated: April 17, 2019
Result type: Reports
opens in document viewer

Major depressive disorder (MDD) is a common, debilitating, and recurrent mental health disorder. Approximately 10% to 30% of patients with MDD will not reach complete clinical remission despite multiple antidepressant pharmacologic approaches — this subpopulation is described as having treatment-resistant depression (TRD). TRD is a more chall...

  • Project Number: EH0075-000